Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Ascelia Pharma AB ( (SE:ACE) ).
Ascelia Pharma announced that Fenja Capital II A/S has requested the conversion of all outstanding convertibles, resulting in the issuance of 2,218,933 new ordinary shares. This conversion increases the total number of outstanding shares and slightly dilutes the existing shares by approximately 1.88%. The company’s cash runway is now extended into the second quarter of 2026, which may impact its financial stability and operational planning.
More about Ascelia Pharma AB
Ascelia Pharma is a biotech company specializing in orphan oncology treatments, focusing on developing and commercializing novel drugs to meet unmet medical needs. The company is headquartered in Malmö, Sweden, and is listed on Nasdaq Stockholm.
Average Trading Volume: 999,504
Technical Sentiment Signal: Buy
Current Market Cap: SEK573.2M
For an in-depth examination of ACE stock, go to TipRanks’ Overview page.